ReviewRenal failure2024
Advancing kidney transplantation in black patients: a genetics-based and personalized approach under NICE, KDIGO, and ERBP guidelines.
Review in Renal failure, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Induction therapy is a critical component of renal transplantation, aimed at reducing delayed graft function (DGF) and improving graft survival. This review assesses the impact of leading large national and international guidelines: National Institute for Health and Care Excellence (NICE), Kidney Disease: Improving Global Outcomes (KDIGO), and European Renal Best Practice (ERBP) propositions, focusing on their applicability to high-risk groups, specifically, on Black patients and those with donor-specific antibodies (DSAs). While NICE guidelines provide a standardized approach favoring basiliximab, concerns arise regarding their suitability for high-risk patients, who may benefit more from potent lymphocyte-depleting agents. KDIGO and ERBP guidelines advocate for personalized approaches, emphasizing genetic diversity and specific patient profiles to tailor immunosuppressive regimens effectively. This review advocates for a paradigm shift toward personalized induction therapy, integrating genetic insights to improve clinical outcomes and address health disparities. By tailoring induction therapies to the genetic and immunological profiles of transplant recipients, healthcare providers can enhance transplant success and ensure equitable healthcare for diverse populations. This approach underscores the importance of personalized medicine in achieving optimal outcomes in renal transplantation. This concern is of particular importance to Black individuals due to the specific genetic markers and health profiles relevant to this group, while recognizing the current gap in data regarding other ethnicities.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.